JP2014520092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520092A5 JP2014520092A5 JP2014511973A JP2014511973A JP2014520092A5 JP 2014520092 A5 JP2014520092 A5 JP 2014520092A5 JP 2014511973 A JP2014511973 A JP 2014511973A JP 2014511973 A JP2014511973 A JP 2014511973A JP 2014520092 A5 JP2014520092 A5 JP 2014520092A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- disease
- autoimmune
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 34
- 208000011580 syndromic disease Diseases 0.000 claims 31
- 230000001363 autoimmune Effects 0.000 claims 24
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims 22
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims 18
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims 18
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims 17
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 16
- 208000023275 Autoimmune disease Diseases 0.000 claims 15
- 206010047115 Vasculitis Diseases 0.000 claims 15
- 208000027866 inflammatory disease Diseases 0.000 claims 15
- 206010061218 Inflammation Diseases 0.000 claims 13
- 230000004054 inflammatory process Effects 0.000 claims 13
- 230000001404 mediated effect Effects 0.000 claims 12
- 206010018364 Glomerulonephritis Diseases 0.000 claims 11
- 241000721454 Pemphigus Species 0.000 claims 10
- 208000010668 atopic eczema Diseases 0.000 claims 10
- 230000001684 chronic effect Effects 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 9
- 230000001154 acute effect Effects 0.000 claims 8
- 230000000172 allergic effect Effects 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 206010003246 arthritis Diseases 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 7
- 206010046851 Uveitis Diseases 0.000 claims 7
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 7
- 201000006417 multiple sclerosis Diseases 0.000 claims 7
- 201000008383 nephritis Diseases 0.000 claims 7
- 208000033808 peripheral neuropathy Diseases 0.000 claims 7
- 208000002574 reactive arthritis Diseases 0.000 claims 7
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 208000015943 Coeliac disease Diseases 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 6
- 206010014599 encephalitis Diseases 0.000 claims 6
- 201000001119 neuropathy Diseases 0.000 claims 6
- 230000007823 neuropathy Effects 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 5
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 206010063837 Reperfusion injury Diseases 0.000 claims 5
- 208000025747 Rheumatic disease Diseases 0.000 claims 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 5
- 206010009887 colitis Diseases 0.000 claims 5
- 201000001981 dermatomyositis Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 4
- 206010015150 Erythema Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010022941 Iridocyclitis Diseases 0.000 claims 4
- 208000016604 Lyme disease Diseases 0.000 claims 4
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 4
- 206010065159 Polychondritis Diseases 0.000 claims 4
- 208000033464 Reiter syndrome Diseases 0.000 claims 4
- 208000034189 Sclerosis Diseases 0.000 claims 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 201000004612 anterior uveitis Diseases 0.000 claims 4
- 230000005784 autoimmunity Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 231100000321 erythema Toxicity 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 230000009610 hypersensitivity Effects 0.000 claims 4
- 210000000822 natural killer cell Anatomy 0.000 claims 4
- 208000005987 polymyositis Diseases 0.000 claims 4
- 201000005671 spondyloarthropathy Diseases 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 206010001889 Alveolitis Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010003267 Arthritis reactive Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 208000017701 Endocrine disease Diseases 0.000 claims 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 208000012309 Linear IgA disease Diseases 0.000 claims 3
- 206010025280 Lymphocytosis Diseases 0.000 claims 3
- 208000000112 Myalgia Diseases 0.000 claims 3
- 208000009525 Myocarditis Diseases 0.000 claims 3
- 201000002481 Myositis Diseases 0.000 claims 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 3
- 208000024376 chronic urticaria Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000002491 encephalomyelitis Diseases 0.000 claims 3
- 208000030172 endocrine system disease Diseases 0.000 claims 3
- 210000003979 eosinophil Anatomy 0.000 claims 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 201000004614 iritis Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 210000001685 thyroid gland Anatomy 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 201000002909 Aspergillosis Diseases 0.000 claims 2
- 208000036641 Aspergillus infections Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 2
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 2
- 208000004554 Leishmaniasis Diseases 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 206010028665 Myxoedema Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010042276 Subacute endocarditis Diseases 0.000 claims 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 2
- 206010043189 Telangiectasia Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- -1 abemil Chemical class 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 claims 2
- 229940043256 calcium pyrophosphate Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000002849 chondrocalcinosis Diseases 0.000 claims 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 208000021921 corneal disease Diseases 0.000 claims 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 235000019821 dicalcium diphosphate Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 206010014801 endophthalmitis Diseases 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 201000002364 leukopenia Diseases 0.000 claims 2
- 231100001022 leukopenia Toxicity 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000037890 multiple organ injury Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 208000003786 myxedema Diseases 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- 230000005298 paramagnetic effect Effects 0.000 claims 2
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000009169 relapsing polychondritis Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 230000000552 rheumatic effect Effects 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 claims 2
- 208000009056 telangiectasis Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- 102100033051 40S ribosomal protein S19 Human genes 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 1
- 206010001076 Acute sinusitis Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 1
- 206010062269 Adrenalitis Diseases 0.000 claims 1
- 201000010000 Agranulocytosis Diseases 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024985 Alport syndrome Diseases 0.000 claims 1
- 206010001881 Alveolar proteinosis Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 208000025494 Aortic disease Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010003487 Aspergilloma Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims 1
- 206010071577 Autoimmune hyperlipidaemia Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006373 Bell palsy Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 201000004813 Bronchopneumonia Diseases 0.000 claims 1
- 201000007155 CD40 ligand deficiency Diseases 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 241000244203 Caenorhabditis elegans Species 0.000 claims 1
- 208000004434 Calcinosis Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 208000018152 Cerebral disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 208000031976 Channelopathies Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 206010010619 Congenital rubella infection Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011258 Coxsackie myocarditis Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 230000006820 DNA synthesis Effects 0.000 claims 1
- 206010011891 Deafness neurosensory Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000021866 Dressler syndrome Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000005235 Echovirus Infections Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014952 Eosinophilia myalgia syndrome Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010059284 Epidermal necrosis Diseases 0.000 claims 1
- 206010053177 Epidermolysis Diseases 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 208000030644 Esophageal Motility disease Diseases 0.000 claims 1
- 208000004332 Evans syndrome Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 206010016952 Food poisoning Diseases 0.000 claims 1
- 208000019331 Foodborne disease Diseases 0.000 claims 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010018366 Glomerulonephritis acute Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010018687 Granulocytopenia Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000008899 Habitual abortion Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 206010019263 Heart block congenital Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101000945342 Homo sapiens Killer cell immunoglobulin-like receptor 2DS4 Proteins 0.000 claims 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims 1
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010058002 Hypoglobulinaemia Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 206010021067 Hypopituitarism Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022557 Intermediate uveitis Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 102100033624 Killer cell immunoglobulin-like receptor 2DS4 Human genes 0.000 claims 1
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims 1
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 201000001779 Leukocyte adhesion deficiency Diseases 0.000 claims 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 claims 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 229910052765 Lutetium Inorganic materials 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000002616 MRI contrast agent Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003423 Mucocele Diseases 0.000 claims 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims 1
- 206010062575 Muscle contracture Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 206010028703 Nail psoriasis Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010071579 Neuronal neuropathy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000014934 Oesophageal motility disease Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 206010072106 Paraneoplastic neurological syndrome Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000008071 Parvoviridae Infections Diseases 0.000 claims 1
- 206010057343 Parvovirus infection Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 claims 1
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 206010036242 Post vaccination syndrome Diseases 0.000 claims 1
- 206010036297 Postpartum hypopituitarism Diseases 0.000 claims 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036697 Primary hypothyroidism Diseases 0.000 claims 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 1
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 230000006819 RNA synthesis Effects 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000021329 Refractory celiac disease Diseases 0.000 claims 1
- 206010038743 Restlessness Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000009895 Sheehan syndrome Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims 1
- 208000027522 Sydenham chorea Diseases 0.000 claims 1
- 206010042938 Systemic candida Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010071574 Testicular autoimmunity Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 201000009365 Thymic carcinoma Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010043784 Thyroiditis subacute Diseases 0.000 claims 1
- 208000003441 Transfusion reaction Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 1
- 206010047141 Vasodilatation Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 241000282485 Vulpes vulpes Species 0.000 claims 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000037855 acute anterior uveitis Diseases 0.000 claims 1
- 208000026816 acute arthritis Diseases 0.000 claims 1
- 231100000851 acute glomerulonephritis Toxicity 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 201000010435 allergic urticaria Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000000469 anti-sperm effect Effects 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 208000029407 autoimmune urticaria Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 206010003882 axonal neuropathy Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims 1
- 230000012085 chronic inflammatory response Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 201000004395 congenital heart block Diseases 0.000 claims 1
- 208000006111 contracture Diseases 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000032625 disorder of ear Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 201000011191 dyskinesia of esophagus Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 208000001031 fetal erythroblastosis Diseases 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 230000006589 gland dysfunction Effects 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000024798 heartburn Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 208000003215 hereditary nephritis Diseases 0.000 claims 1
- 208000012410 herpes zoster dermatitis Diseases 0.000 claims 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 201000006747 infectious mononucleosis Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000021646 inflammation of heart layer Diseases 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 210000005067 joint tissue Anatomy 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229910052746 lanthanum Inorganic materials 0.000 claims 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 208000010325 limbic encephalitis Diseases 0.000 claims 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000005158 lymphoid interstitial pneumonia Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 208000008275 microscopic colitis Diseases 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 208000028780 ocular motility disease Diseases 0.000 claims 1
- 208000005963 oophoritis Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 208000029308 periodic paralysis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 108700028325 pokeweed antiviral Proteins 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 229960003387 progesterone Drugs 0.000 claims 1
- 239000000186 progesterone Substances 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 claims 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims 1
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 229910052706 scandium Inorganic materials 0.000 claims 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 201000006476 shipyard eye Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000021595 spermatogenesis Effects 0.000 claims 1
- 201000006923 sphenoid sinusitis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000003393 splenic effect Effects 0.000 claims 1
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000007497 subacute thyroiditis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 210000001745 uvea Anatomy 0.000 claims 1
- 230000024883 vasodilation Effects 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489806P | 2011-05-25 | 2011-05-25 | |
| US61/489,806 | 2011-05-25 | ||
| PCT/IB2012/001512 WO2012160448A2 (en) | 2011-05-25 | 2012-05-25 | Anti-kir antibodies for the treatment of inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520092A JP2014520092A (ja) | 2014-08-21 |
| JP2014520092A5 true JP2014520092A5 (enExample) | 2015-05-21 |
| JP6342325B2 JP6342325B2 (ja) | 2018-06-13 |
Family
ID=46785768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511973A Active JP6342325B2 (ja) | 2011-05-25 | 2012-05-25 | 炎症性障害の治療のための抗ｋｉｒ抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9067997B2 (enExample) |
| EP (1) | EP2714741B1 (enExample) |
| JP (1) | JP6342325B2 (enExample) |
| KR (1) | KR102046666B1 (enExample) |
| CN (1) | CN103717619B (enExample) |
| AR (1) | AR086582A1 (enExample) |
| AU (1) | AU2012260601B2 (enExample) |
| BR (1) | BR112013030017A2 (enExample) |
| CA (1) | CA2837184C (enExample) |
| EA (1) | EA036545B1 (enExample) |
| ES (1) | ES2765874T3 (enExample) |
| IL (1) | IL229582B (enExample) |
| MX (1) | MX347514B (enExample) |
| SG (2) | SG10201603962TA (enExample) |
| TW (1) | TWI560200B (enExample) |
| WO (1) | WO2012160448A2 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060079180A (ko) * | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| US20090191213A9 (en) * | 2003-07-02 | 2009-07-30 | Novo Nordisk A/S | Compositions and methods for regulating NK cell activity |
| DK2287195T3 (da) * | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| US20090196850A1 (en) * | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| CA2675291C (en) | 2007-01-11 | 2017-05-23 | Novo Nordisk A/S | Killer ig-like receptor (kir) antibodies, formulations, and uses thereof |
| PL3581105T3 (pl) | 2010-05-08 | 2022-11-28 | The Regents Of The University Of California | Urządzenie do wczesnego wykrywania owrzodzenia przez skanowanie uwodnienia podnaskórkowego |
| AU2013327116C1 (en) | 2012-10-02 | 2018-08-30 | Bristol-Myers Squibb Company | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer |
| GB201304662D0 (en) * | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| WO2015069785A1 (en) | 2013-11-06 | 2015-05-14 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| CN106132989B (zh) * | 2014-03-14 | 2020-06-19 | 先天制药公司 | 具有增加的稳定性的人源化抗体 |
| WO2016030488A1 (en) * | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| US20160272709A1 (en) * | 2015-02-12 | 2016-09-22 | The Regents Of The University Of Michigan | Anti-kir antibodies |
| AU2016230827B2 (en) * | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| NZ735820A (en) | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CN107847445B (zh) * | 2015-04-20 | 2021-07-20 | 加利福尼亚大学董事会 | 包封的气体或部分真空ct造影材料 |
| AU2016250527B2 (en) | 2015-04-24 | 2021-01-14 | Bruin Biometrics, Llc | Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements |
| JP6644478B2 (ja) * | 2015-04-28 | 2020-02-12 | 国立大学法人東北大学 | チオプリン製剤による副作用の危険性の判定方法 |
| DE112016002056T5 (de) | 2015-05-06 | 2018-02-08 | Snipr Technologies Limited | Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| WO2016208880A1 (ko) * | 2015-06-26 | 2016-12-29 | 주식회사 파마리서치프로덕트 | 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물 |
| KR102733066B1 (ko) * | 2015-06-26 | 2024-11-21 | 주식회사 파마리서치 | 어류의 정액 또는 정소로부터 분리된 dna 단편 혼합물을 포함하는 허혈성 장염의 예방 또는 치료용 조성물 |
| CA2986705A1 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | A cxcr4 inhibitor and a pdi antagonist for use in treating cancer |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CN108884159A (zh) | 2015-11-07 | 2018-11-23 | 茂体外尔公司 | 用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物 |
| KR20180093961A (ko) * | 2015-12-15 | 2018-08-22 | 메모리얼 슬로안-케터링 캔서 센터 | 조직 구별, 예를 들어, 수술 중 시각화를 위한 영상화 시스템 및 방법 |
| US11213538B2 (en) | 2016-02-16 | 2022-01-04 | General Incorporated Association Pharma Valley Project Supporting Organization | Agent for overcoming immunosuppression and use thereof |
| EP4169942A1 (en) | 2016-03-11 | 2023-04-26 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| US11096965B2 (en) | 2016-04-04 | 2021-08-24 | The Regents Of The University Of California | Compositions and methods related to polycytotoxic T cells |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| HRP20240617T1 (hr) | 2016-05-20 | 2024-07-19 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| CN105943048B (zh) * | 2016-06-27 | 2018-11-13 | 首都医科大学附属北京胸科医院 | 一种基于核磁共振技术区分结核性脑膜炎和病毒性脑膜炎的方法及其应用 |
| US10858431B2 (en) | 2016-06-30 | 2020-12-08 | Trellis Bioscience, Llc | Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| JP7041136B2 (ja) | 2016-10-12 | 2022-03-23 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｔｕｓｃ２免疫療法のための方法および組成物 |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| CA3042101C (en) | 2017-02-03 | 2024-04-09 | Bruin Biometrics, Llc | Measurement of edema |
| NZ773584A (en) | 2017-02-03 | 2025-07-25 | Bbi Medical Innovations Llc | Measurement of susceptibility to diabetic foot ulcers |
| FI3515296T3 (fi) | 2017-02-03 | 2023-12-21 | Bbi Medical Innovations Llc | Kudoksen elinkelpoisuuden mittaus |
| KR20250036268A (ko) | 2017-03-31 | 2025-03-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| JP2020536894A (ja) | 2017-10-15 | 2020-12-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 腫瘍処置法 |
| MX2020005138A (es) * | 2017-11-16 | 2020-08-17 | Bruin Biometrics Llc | Tratamiento estrategico de ulceras por presion por el uso de valores humedad subepidermica. |
| AU2018386193B2 (en) * | 2017-12-13 | 2025-04-24 | Momenta Pharmaceuticals, Inc. | FcRn antibodies and methods of use thereof |
| GB2584226B (en) | 2018-02-09 | 2022-06-22 | Bruin Biometrics Llc | Detection of tissue damage |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| EP4066851A1 (en) | 2018-03-25 | 2022-10-05 | SNIPR Biome ApS. | Treating & preventing microbial infections |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| CA3109658A1 (en) * | 2018-08-13 | 2020-02-20 | The Regents Of The University Of Michigan | Use of jak inhibitors in the treatment of amyotrophic lateral sclerosis (asl) |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| DK4283799T3 (da) | 2018-10-11 | 2025-04-22 | Bruin Biometrics Llc | Indretning med engangselement |
| CN113166762B (zh) | 2018-12-21 | 2025-01-14 | 瓦莱里奥治疗公司 | 新的偶联核酸分子及其用途 |
| CN109675037B (zh) * | 2019-01-25 | 2021-09-14 | 南方医科大学 | Atp及其受体在制备治疗自闭症药物中的应用 |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| JP2022534982A (ja) | 2019-05-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよびその使用 |
| KR20220035394A (ko) | 2019-06-21 | 2022-03-22 | 에이치씨더블유 바이올로직스, 인크. | 다중-사슬 키메라 폴리펩티드 및 이의 용도 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US11851490B2 (en) * | 2019-08-15 | 2023-12-26 | Northwestern University | Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification |
| CN112574281B (zh) * | 2019-09-27 | 2022-03-29 | 暨南大学 | 一种成对免疫球蛋白样受体b结合肽及其衍生物与应用 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
| EP4204453A1 (en) | 2020-08-31 | 2023-07-05 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| MX2023009100A (es) * | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| US11642075B2 (en) | 2021-02-03 | 2023-05-09 | Bruin Biometrics, Llc | Methods of treating deep and early-stage pressure induced tissue damage |
| CN115120620A (zh) * | 2021-03-26 | 2022-09-30 | 上海雷允上药业有限公司 | 一种六神丸的用途以及药物组合物和用途 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023076876A1 (en) * | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| IL313439A (en) | 2021-12-16 | 2024-08-01 | Valerio Therapeutics | New conjugated nucleic acid molecules and their uses |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| AU2023393653A1 (en) | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| CN117031044B (zh) * | 2023-10-07 | 2024-01-02 | 首都医科大学附属北京天坛医院 | 一种预测卒中相关性肺炎的生物标志物和试剂盒及诊断设备 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN118987020B (zh) * | 2024-08-23 | 2025-09-05 | 天津医科大学 | 金诺芬在制备错配修复缺陷肿瘤药物中的应用 |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
| DE3134803A1 (de) | 1981-09-02 | 1983-03-17 | Brown, Boveri & Cie Ag, 6800 Mannheim | "verfahren zur reinigung von hohlleitern gekuehlter elektrischer maschinen und apparate" |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5580756A (en) | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US6172208B1 (en) | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
| DE69333366T2 (de) | 1992-10-30 | 2004-09-16 | The General Hospital Corp., Boston | Ein neues zellzyklus kontrollprotein |
| WO1994021293A1 (en) | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69433036T2 (de) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | Aminoderivatisierte nukleoside und oligonukleoside |
| ATE306930T1 (de) | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US5801155A (en) | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6444806B1 (en) | 1996-04-30 | 2002-09-03 | Hisamitsu Pharmaceutical Co., Inc. | Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US20040038894A1 (en) | 1996-12-31 | 2004-02-26 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Compounds for modulating cell negative regulations and biological applications thereof |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| AU764180B2 (en) | 1998-07-28 | 2003-08-14 | Regents Of The University Of California, The | Nucleic acids encoding a G-protein coupled receptor involved in sensory transduction |
| US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| US6696686B1 (en) | 1999-06-06 | 2004-02-24 | Elgems Ltd. | SPECT for breast cancer detection |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US6395437B1 (en) | 1999-10-29 | 2002-05-28 | Advanced Micro Devices, Inc. | Junction profiling using a scanning voltage micrograph |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| DK1436003T3 (da) | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| AU2002359464A1 (en) | 2001-11-30 | 2003-06-17 | Genvec, Inc. | Angiopioetin related factors |
| CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| AU2003294930B2 (en) | 2002-12-23 | 2008-12-04 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same |
| CN1852924A (zh) * | 2003-07-02 | 2006-10-25 | 依奈特制药公司 | Pan－kir2dl nk－受体的抗体及其在诊断及治疗中的应用 |
| KR20060079180A (ko) * | 2003-07-02 | 2006-07-05 | 노보 노르디스크 에이/에스 | Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법 |
| PT1648507T (pt) * | 2003-07-24 | 2017-03-20 | Innate Pharma Sa | Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk |
| WO2005037306A1 (en) | 2003-10-17 | 2005-04-28 | Novo Nordisk A/S | Combination therapy |
| EP1744734A2 (en) | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
| WO2005113503A2 (en) * | 2004-05-21 | 2005-12-01 | Pfizer Products Inc. | Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine |
| DK2287195T3 (da) * | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| EP3026063A1 (en) * | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| US20090196850A1 (en) | 2005-01-06 | 2009-08-06 | Novo Nordisk A/S | Anti-Kir Combination Treatments and Methods |
| PL1836225T3 (pl) * | 2005-01-06 | 2012-05-31 | Novo Nordisk As | Czynniki wiążące kir i sposoby ich stosowania |
| ES2384466T3 (es) * | 2005-01-06 | 2012-07-05 | Novo Nordisk A/S | Composiciones y procedimientos de tratamiento de una infección viral |
| CA2623109C (en) * | 2005-10-14 | 2019-02-19 | Innate Pharma | Nk cell-depleting antibodies for treating immunoproliferative disorders |
| CA2675291C (en) * | 2007-01-11 | 2017-05-23 | Novo Nordisk A/S | Killer ig-like receptor (kir) antibodies, formulations, and uses thereof |
| US20110256121A1 (en) * | 2008-10-22 | 2011-10-20 | The Regents Of The University Of Michigan | Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases |
| EP2519239B1 (en) * | 2009-12-29 | 2017-03-08 | Gamida Cell Ltd. | Methods for enhancing natural killer cell proliferation and activity |
| CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| US9844593B2 (en) * | 2010-11-22 | 2017-12-19 | Innate Pharma Sa | Methods for treatment of recurrent hematological malignancies |
| KR102009106B1 (ko) * | 2018-01-11 | 2019-08-08 | 고려대학교 산학협력단 | 사용자 인증 방법 |
-
2012
- 2012-05-25 US US13/481,161 patent/US9067997B2/en active Active
- 2012-05-25 EA EA201391755A patent/EA036545B1/ru not_active IP Right Cessation
- 2012-05-25 ES ES12753810T patent/ES2765874T3/es active Active
- 2012-05-25 JP JP2014511973A patent/JP6342325B2/ja active Active
- 2012-05-25 BR BR112013030017-5A patent/BR112013030017A2/pt not_active IP Right Cessation
- 2012-05-25 WO PCT/IB2012/001512 patent/WO2012160448A2/en not_active Ceased
- 2012-05-25 CA CA2837184A patent/CA2837184C/en active Active
- 2012-05-25 SG SG10201603962TA patent/SG10201603962TA/en unknown
- 2012-05-25 AU AU2012260601A patent/AU2012260601B2/en not_active Ceased
- 2012-05-25 MX MX2013013635A patent/MX347514B/es active IP Right Grant
- 2012-05-25 CN CN201280037229.1A patent/CN103717619B/zh active Active
- 2012-05-25 SG SG2013086137A patent/SG195082A1/en unknown
- 2012-05-25 EP EP12753810.6A patent/EP2714741B1/en active Active
- 2012-05-25 TW TW101118857A patent/TWI560200B/zh not_active IP Right Cessation
- 2012-05-25 KR KR1020137033948A patent/KR102046666B1/ko not_active Expired - Fee Related
- 2012-05-28 AR ARP120101874A patent/AR086582A1/es unknown
-
2013
- 2013-11-24 IL IL229582A patent/IL229582B/en active IP Right Grant
-
2015
- 2015-06-29 US US14/753,886 patent/US20150376275A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520092A5 (enExample) | ||
| ES2649155T3 (es) | Anticuerpos anti-OX40 y procedimientos de uso de los mismos | |
| US10414825B2 (en) | Anti-MCAM antibodies and associated methods of use | |
| AU2013206788B2 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| JP2019522680A5 (enExample) | ||
| ES3004282T3 (en) | Anti-fcrn antibodies | |
| ES2765874T3 (es) | Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios | |
| ES2402650T3 (es) | Métodos de purificación de anticuerpos anti A beta | |
| ES2699716T3 (es) | Moléculas de anticuerpo que tienen especificidad por OX40 humano | |
| BR112020002012A2 (pt) | anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
| US10875916B2 (en) | Nucleic acid molecules encoding monoclonal antibodies specific for IL-17F | |
| JP2021500391A5 (enExample) | ||
| JP2012139224A5 (enExample) | ||
| WO2012170071A1 (en) | Mcam antagonists and methods of treatment | |
| WO2018223140A1 (en) | Anti-mcam antibodies and associated methods of use | |
| US11993647B2 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| ES2718226T3 (es) | Accionador telescópico lineal | |
| WO2025247924A1 (en) | ANTI-IFN-α2 MONOCLONAL ANTIBODIES | |
| WO2025247913A1 (en) | Anti-ifn-omega1 monoclonal antibodies | |
| ES2726539T3 (es) | Método para proporcionar autoanticuerpos monoclonales con especificidad deseada | |
| HK40013169A (en) | Anti-mcam antibodies and associated methods of use | |
| Paantjens et al. | The Occurance of IgM and IgG Antibodies against HLA or MICA after Lung Transplantation | |
| HK1212256B (en) | Anti-mcam antibodies and associated methods of use |